Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

236 results about "Calcium Channel Blocking Drugs" patented technology

Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are several medications that disrupt the movement of calcium (Ca2+. ) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.

Compounds and methods for the treatment of urogenital disorders

InactiveUS6987129B2Reduce painLess discomfortBiocidePeptide/protein ingredientsDiseaseFemale Sexual Arousal Disorder
The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and / or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).
Owner:STREHKEHN INT LTD

Fasudil in combination therapies for the treatment of pulmonary arterial hypertension

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing pulmonary arterial hypertension and / or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.
Owner:ASAHI KASEI PHARMA

Inhalable formulations for treating pulmonary hypertension and methods of using same

The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
Owner:DEY

Compositions and methods for enhancing cognitive function and synaptic plasticity

InactiveUS20060089335A1Improve cognitive functionEnhance synaptic plasticityBiocidePeptide/protein ingredientsNR1 NMDA receptorAction potential firing
The present invention provides compositions and methods for enhancing cognitive function and synaptic plasticity. According to the method, Ca++ influx into excitatory neurons (nerve cells) is decreased by treatment with a number of different agents including divalent cations (e.g., Mg++), GABAB agonists, GABAA agonists, calcium channel blockers, and / or compounds that decrease action potential firing such as sodium channel blockers. Decreasing Ca++ influx results in increased synaptic plasticity and enhanced cognitive function. In particular, decreasing Ca++ influx associated with uncorrelated neural activity results in long-lasting increases in synaptic plasticity and cognitive function. This is achieved by administration of agents that cause a voltage-dependent block of NMDA receptors (e.g., divalent cations such as Mg++) or by administration of GABAB agonists such as baclofen. The invention further provides screening methods useful in identifying compounds that enhance synaptic plasticity and cognitive function.
Owner:MASSACHUSETTS INST OF TECH

Methods and solutions for storing donor organs

A method of preserving, storing and transplanting mammalian donor organs. The method includes the cooling of refrigeration preservation, loading pre-freezer preservation, cryopreservation and washing solutions at least containing polyvinylpyrrolidone, a calcium channel blocker, a nucleoside, potassium chloride, polyethylene glycol, at least one amino acid, and a steroid to a temperature of 2° to 4° C. and / or of 0° to 2° C., harvesting a donor organ, perfusing it with one or more of the solution, immersing it in one or more of the solutions and storing it at a temperature above 0° C. or at a temperatures below 0° C. The cryopreservation solution also contains cryopreservative agents. Preserved organs may be transplanted directly from refrigeration storage or from freezer storage by cooling the washing refrigeration preservation solutions to 2° to 4° C., perfusing the organ with washing solution and then preservation solution, and transplanting it.
Owner:HUMAN BIOSYST

Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HCl (Benzenacetonitrile, (±)-alpha[3[[2-(3,4-dimethoxyphenyl) ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.
Owner:SCHUH JOSEPH R

Inhibition of olfactory neurosensory function to treat eating disorders and obesity

The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal mucosa, as well as screening methods for drugs to be used in treating obesity or associated disorders.
Owner:COMPELLIS PHARMA

Urological medical devices for release of therapeutic agents

InactiveUS20080234659A1High quantity of drugAvoid the needNervous disorderSurgeryAlpha-adrenergic blockersTherapeutic effect
According to an aspect of the present invention, urological medical devices are provided, which contain one or more urologically beneficial agents selected from alpha-adrenergic blockers, calcium channel blockers, and combinations thereof, among others. The urological devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the urologically beneficial agent is released. Such agents are urologically beneficial, for example, in that they may relieve pain and / or discomfort associated with the medical device and / or act as stone expulsion agents (i.e., they facilitate stone passage), among other benefits. According to an aspect of the present invention, a method of treating kidney stones is provided which comprises: (a) diagnosing the presence of kidney stones within a subject and (b) implanting or inserting a urological medical device into the subject which contains at least one urologically beneficial agent. The medical device is adapted to release the at least one urologically beneficial agent in vivo in an amount effective to promote kidney stone expulsion.
Owner:BOSTON SCI SCIMED INC

Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, angina and congestive heart failure. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker amlodipine and the aldosterone receptor antagonist eplerenone.
Owner:GD SEARLE & CO

Urological medical devices for release of prostatically beneficial therapeutic agents

According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic / antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.
Owner:BOSTON SCI SCIMED INC

Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory

The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.
Owner:HANALL PHARMA CO LTD

Method of healing skin wounds in mammals and a composition therefor

This invention pertains to therapeutic antibacterial / antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and / or antifungal agents and / or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial / antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.
Owner:PESHOFF MICKEY L

Co-formulations or kits of bioactive agents

InactiveUS20070098778A1BiocideMetabolism disorderHMG-CoA reductaseMeglitinide
Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPARα / γ agonist, PPARγ agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotension II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative; wherein: in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinedione or dual PPARα / γ agonist with an angiotension II receptor antagonist, one or more of the following applies: (I) one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or (II) the co-formulation or kit comprises (A) a biguanide and a thiazolidinedione and (B) one or more group (b) bioactive agents.
Owner:ABEILLE PHARMA

Antihypertensive therapy

InactiveUS20090221549A1Beneficial effect on renal functionLower blood pressureBiocideAnimal repellantsAmbulatoryAnti hypertensive treatment
A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and / or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.
Owner:ABBOTT GMBH & CO KG

Anticancer calcium channel blockers

The present invention is directed to compounds useful as cancer cell inhibitors, compositions containing such compounds and methods for inhibiting proliferation of electrically non-excitable cells.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND +1

Diaryl-cyclylalkyl derivatives as calcium channel blockers

InactiveUS20090270338A1High activityNervous disorderOrganic chemistryT-type calcium channelCalcium channel activity
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and / or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted N-cyclylalkyl-diphenylpropanamide derivatives as shown in formula (1).
Owner:ZALICUS PHARMA LTD (CA)

Topical therapeutic formulations

The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.
Owner:HYBRID MEDICAL

Di-t-butylphenyl piperazines as calcium channel blockers

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and / or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing di-t-butyl phenyl piperazine derivatives of the general formula (1).
Owner:ZALICUS PHARMA LTD (CA)

Methods And Solutions For Storing Donor Organs

InactiveUS20070009880A1Reduction of interstitial edemaDead animal preservationPolyethylene glycolPotassium
The present invention provides methods of preserving, storing and transplanting mammalian donor organs. The method includes the cooling of refrigeration preservation, loading pre-freezer preservation, cryopreservation, and washing solutions at least containing polyvinylpyrrolidone, a calcium channel blocker, a nucleoside, potassium chloride, polyethylene glycol, at least one amino acid, and a steroid to a temperature of 2° to 4° C. and / or of 0° to 2° C., harvesting a donor organ, perfusing it with one or more of the solution, immersing it in one or more of the solutions and storing it at a temperature above 0° C. or at a temperatures below 0° C. including −20° C., −80° C. and −196° C. The cryopreservation solution also contains cryopreservative agents. Preserved organs may be transplanted directly from refrigeration storage or from freezer storage by cooling the washing refrigeration preservation solutions to 2° to 4° C., perfusing the organ with washing solution and then preservation solution, and transplanting it.
Owner:HUMAN BIOSYST

Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt

The invention relates to a formula of a sartan compound or a pharmaceutically acceptable salt thereof and a calcium channel blocker or a pharmaceutically acceptable salt, which belong to the technical field of medicine. The formula comprises the following components by weight proportion: 5-200 parts of [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and a carboxylic acid compound and salt thereof and 0.5-60 parts of a calcium ion retarder; the preferable scheme is 20-100 parts of the [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and the carboxylic acid compound and the salt thereof and 1-30 parts of the calcium ion retarder; the administration forms can be one of the following forms such as oral administration, inhalation, subcutaneous administration, sublingual administration, intramuscular administration, intravenous administration, transdermal administration, local administration or rectal administration. In the formula of the invention, an antihypertensive I and the calcium channel blocker or the pharmaceutically acceptable salt are studied; thus a preparation with a new formula for treating hypertension is provided. The preparation is characterized by low dosage, obvious blood pressure lowering effect and little adverse reaction.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products